ISAL 2019 | BCL-2 targeting in AML: updates

Marina Konopleva

Marina Konopleva, MD, PhD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the latest updates in BCL-2 targeting for acute myeloid leukemia (AML) at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany. Prof. Konopleva highlights the importance of this therapy for elderly patients who cannot tolerate other therapies, while it also has the potential to be combined with more intensive treatments in younger patients.

Share this video